Autopsy report · NCT00740545

Prevention of Unexplained Recurrent Abortion by Enoxaparine

“Stopped for futility”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 4 months after it had already started.
• Ran for about 7 years 5 months before it stopped.
• 258 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

University Hospital, Brest

Sponsor type

University, hospital or other

Conditions

Alive and Viable Births

Interventions

enoxaparine 40 mg daily; placebo

Participants

258

Sites

7

Countries

France

Trials that died the same way

• Cerebral Microembolism in the Critically Ill With Acute Kidney Injury
  “Futility” (75% match in meaning)
• Safety of FMT: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infection
  “for futility” (72% match in meaning)
• Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
  “The study stopped due to futility” (69% match in meaning)
• Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
  “Project was stopped due to futility” (68% match in meaning)
• Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage But no Stents
  “due to futility” (67% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.